FEB 2 2 2001

# 4



1406-1414, (Aug. 15, 1998) -

D.R.,

et

Pharmacokinetics, 26 (4), pp. 259-274,

al.,

TECH CENTER 1600/2900

Sheet 1 of 4

Form 1449\*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.: 103.022US1

Applicant: Dennis A. Carson et al.

Filing Date: August 9, 2000

Group: 1614

Serial No. 09/634,207

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
WI	3,843,681	10/22/1974	Demerson et al.	260	326.14 R	06/01/71	
<del>''/`</del>	4,337,760	07/06/1982	Rubin	128	1 R	10/31/79	
<del>-  </del>	£ 4,337,760 £ 5,561,151	10/01/1996	Young et al.	514	411	01/04/95	
<del></del>	5,811,558	09/22/1998	Adger et al.	548	427	04/11/95	
TV	5,955,504	09/21/1999	Wechter et al.	514	568	03/13/95	
-1-0 V- 1	2 J, 933, 304	05/21/1555	weeneer ee ar.	311		22, 22, 23	
		FC	REIGN PATENT DOCUMEN	TS			
Examiner	-/		Country	Class	Subclass	Translation Yes No	
mitial /		01/20/2000	PCT	A61K	31/40		
1	2 00/02333 2 00/13410	03/09/2000	PCT	H04N	5/76		
	96/28148	09/19/1996	PCT	A61K	31/19		
-	98/09603	03/12/1998	PCT	A61K			
MT	98/18490	05/07/1998	PCT	A61K	45/06		
_		,					
			OTHER DOCUMENTS				
Examiner Initial		(Including	Author, Title, Date, Pertinent Pa	iges, Etc.)			
	Abramson,	S.B., et a	al., "The Mechanis	ms of A	ction of	Nonsteroida	
TMI		matory Drugs",	Arthritis & Rheumat	ism, 32 (1	L, pp. 1-9	9, (Jan. 1989).	
	Alexanian	R et al	"The Treatment of M	ultiple Mv	eloma", T	he New Englan	
I	Journal of	Medicine, 330	<u>(7)</u> , pp. 484-489,	(Feb. 17,	1994),		
<del></del>						for Pefractor	
-1	Barlogie, I	Barlogie, B., et al., "Prognostic Factors with High-Dose Melphalan for Refractory					
		Multiple Myeloma", <u>Blood, 72 (6)</u> , pp. 2015-2019, (Dec. 1988).					
			ultiple Myeloma", <u>Ne</u>	w England	Journal o	f Medicine, 33	
	<b>1</b> (00)	1657-1664, (Ju	ne 5 1997).				

Examiner 200	Date Considered	4/29/02
*Substitute Disclosure Statement Form (PTO	-1449)	•

Journal of Chromatography, 621 (2), pp. 199-207, (Nov. 24, 1993) -

"Etodolac

Bellosillo, B., et al., "Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells", Blood, 92 (4), pp.

Clinical

(1994) -

Pharmacokinetics",

Clinical

<sup>\*\*</sup>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





THE 2 I 200 GO

TECH CENTER 1600/2900

Sheet 2 of 4

Form 1449\*

Atty. Docket No.: 103.022US1

Serial No. 09/634,207

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Dennis A. Carson et al.

Filing Date: August 9, 2000

Group: 1614

## OTHER DOCUMENTS

\*\*Examiner Initial (Including Author, Title, Date, Pertinent Pages, Etc.)

T	M	ų	Carson, D.A., et al., "Oral Antilymphocyte Activity and Induction of Apoptosis /by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine", Proc. Natl. Acad. Sci. USA, 89 (7), pp. 2970-2974, (Apr. 1992).
		٧	Chinetti, G., et al., "Activation of Proliferator-activated Receptors $\alpha$ and $\gamma$ Induces Apoptosis of Human Monocyte-derived Macrophages", The Journal of Biological Chemistry, 273 (40), pp. 25573-25580, (Oct. 2, 1998).
		į	Cunningham, D., et al., "High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology, 12 (4)</u> , pp. 764-768, (April 1994).
	,	~	Demerson, C.A., et al., "Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids", Journal of Medicinal Chemistry, 19 (3), pp. 391-395, (1976).
	t	À	Demerson, C.A., et al., "Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers", <u>J. Med.</u> Chem., 26 (12), pp. 1778-1780, (Dec. 1983).
$\cdot $	6	\	Drachenberg, D.F., et al., "Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation", <u>Seminars in Surgical Oncology, 18 (1)</u> , pp. 37-44, (Jan/Feb. 2000).
		<	Duffy, C.P., et al., "Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)", European Journal of Cancer, 34 (8), pp. 1250-1259, (July 1998).
		~	Hahnfeld, L.E., et al., "Prostate Cancer", <u>The Medical Clinics of North America</u> - The Aging Male Patient, 83 (5), pp.1231-1245, (Sept. 1999) .
		<b>\</b>	Harousseau, J.L., et al., "Double-Intensive Therapy in High-Risk Multiple Myeloma", Blood, 79 (11), pp. 2827-2833, (June 1, 1992) -
		1	Krajewski, S., et al., "Detection of Multiple Antigens on Western Blots", Analytical Biochemistry, 236 (2), Article No. 0160, pp. 221-228, (May 1996)
		<u></u>	Landis, S.H., et al., "Cancer Statistics, 1998", <u>CA Cancer J. Clin., 48 (1)</u> , pp. 6-29, (1998).
N	VÍ	V	Lee, D.H., et al., "Proteasome Inhibitors: Valuable New Tools For Cell Biologists", Trends in Cell Biology, 8, pp. 397-403, (1998)

Examiner

Date Considered 4/29/07

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





TECH CENTER 1600/2900

Sheet 3 of 4

Form 1449\*

Atty. Docket No.: 103.022US1

Serial No. 09/634,207

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Dennis A. Carson et al.

Filing Date: August 9, 2000

Group: 1614

(Use several sheets if necessary)

OTHER DOCUMENTS

\*\*Examiner Initial (Including Author, Title, Date, Pertinent Pages, Etc.)

mr.	Lehmann, J.M., et al., "Peroxisome Proliferator-activated Receptors $\alpha$ and $\gamma$ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs", The Journal of Biological Chemistry, 272 (6), pp. 3406-3410, (Feb. 7, 1997).
	Leoni, L.M., et al., "Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2'-deoxyadenosine 5'-triphosphate and Cytochrome C", PNAS, USA, 95 (16), pp. 9567-9571, (Aug. 4, 1998).
	Lochmüller, C.H., et al., "Chromatographic Resolution of Enantiomers Selective Review", Journal of Chromatography, 113 (3), pp. 283-302, (Oct. 22, 1975),
4	Martel, R.R., et al., "Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats", <u>Canadian Journal of Physiology and Pharmacology, 54 (3)</u> , pp. 245-248, (June 1976)
l <sub>e</sub>	Mooney, P.T., et al., "Cell Pathways' Exisulind 'Aptosyn' Demonstrates Potential to Delay Hormone Therapy in Post-Prostatectomy Men at Risk of Prostate Cancer Recurrence", <a href="http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html">http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html</a> , 3 p., (May 2000).
Not alal	Recurrence", <a href="http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html">http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html</a> , 3 p., (May 2000)  PNardella, F.A., et al., "Enhanced Clearance of Leukemic Lymphocytes in B Cell Chronic Lymphocytic Leukemia (CLL) with Etodolac", <a href="https://example.com/arthritis.com/arth&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;·&lt;/td&gt;&lt;td&gt;Ricote, M., et al., " peroxisome="" proliferator-activated="" receptor-<math="" the="">\gamma is a Negative Regulator of Macrophage Activation", Nature, 391, pp. 79-82, (Jan. 1, 1998)</a>
	Riedel, D.A., et al., "The Epidemiology of Multiple Myeloma", Hematology/Oncology Clinics of North America, Multiple Myeloma, 6 (2), pp. 225-247, (April 1992)
✓	Royall, J.A., et al., "Evaluation of 2',7'-Dichlorofluorescin and Dihydrorhodamine 123 as Fluorescent Probes for Intracellular $\rm H_2O_2$ in Cultured Endothelial Cells", Archives of Biochemistry and Biophysics, 302 (2), pp. 348-355, (May 1, 1993),
M	Shiff, S.J., et al., "Nonsteroidal Antiinflammatory Drugs Inhibit the Proliferation of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis", Experimental Cell Research, 222, Article No. 0023, pp. 179-188, (1996),

Examiner Date Considered 4/29/02	_
----------------------------------	---

Sheet 4 of 4

Form 1449\*

Atty. Docket No.: 103.022US1

Serial No. 09/634,207

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Dennis A. Carson et al.

Filing Date: August 9, 2000

P E Group: 1614

OTHER DOCUMENTS

\*\*Examiner Initial (Including Author, Title, Date, Pertinent Pages, Etc.)



Tang, D.G., et al., "Target to Apoptosis: A Hopeful Weapon for Prostate Cancer", pp. 284-293, (1997) \* The Prostate, Wang, X., et al., "Antipoptotic Action of 1,25-Dihydroxyvitamin D<sub>3</sub> Is Associated lphaith Increased Mitochondrial MCL-1 and RAF-1 Proteins and Reduced Release of Cytochrome c", Experimental Cell Research, 235 (1), Article No. EX973667, pp. 210-217, (1997). Wechter, W.J., et al., "E-7869 (R-Flurbiprofen) Inhibits Progression of Prostate Cancer in the TRAMP Mouse", Cancer Research, 60, pp. 2203-2208, (April 15, 2000) -"Aspirin, Non-Steroidal Anti-Inflammatory Drugs and et al., Protection from Colorectal Cancer: a Review of the Epidemiological Evidence", pp. 137-141, (1996). Scandinavian Journal of Gastroenterology, 31 (Suppl. 220), Wilen, S.H., et al., "Strategies In Optical Resolutions", <u>Tetrahedron, 33 (21)</u>, Tetrahedron Report Number 38, pp. 2725-2736, (1977) -

RECEIVED
FEB 2 2 2001
TECH CENTER 1600/2900

Examiner Allom	Date Considered	4/29/	102

PTG/SB/084/(10-0)
Approved for use through 10/31/2002 (10:8 85)-000
US Patent & Trademark Office. U.S. DEPARTMENT OF COMMERC
ork Reduction Act of 1995, no persons are required to respond to a cofection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 09/634207 STATEMENT BY APPLICANT August 9, 2000 Filing Date **First Named Inventor** Carson, Dennis **Group Art Unit** 1624 Truong, Tamthom **Examiner Name** Attorney Docket No: 00103.022US1 Sheet 1 of 1

	US PATENT DOCUMENTS					
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subcla ss	T²
111/1	EP-0289262	11/02/1986	Venuti, M. C., et al	C07C	93/00_	
TNT	DE 2226 340	03/15/1973	DEMERSON CT. M.	C07D	27/56	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
TNY	1	BERENDES, U.,,et al., "Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine", Enantiomer, 1. Abstract Only, Chemical Abstracts, Abstract No. 126.2070646, (1996),415-422				
		BRENNA, E.,,et al., "New Enzymatic and Chemical Approaches to Enantiopure Etodolac", Tetrahedron, 53, (1997),17769-17780				
	<b>/</b>	VAN BREEMEN, RB. ,et al. ,"Characterization of Oxygen-Linked Glucuronides by Laser Desorption Mass Spectrometry", <u>Biomed. Mass Spectrom.</u> , 11, Abstract Only, Chemical Abstracts, Abstract No. 101:106777c,(1984),278-283				
TNT		VENUTI, MC., et al., "Synthesis and Biological Evaluation of omega-(N,N,N-trialkylammonium)alkyl Esters and Thioesters of Carboxylic Acid Nonsteroidal Antiinflammatory Agents", Pharm. Res., 6, Abstract Only, Chemical Abstracts, Abstract No. 112:111681y, (1989), 867-873				

**EXAMINER** 

**DATE CONSIDERED**